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Abstract
Purpose Children with acute lymphoblastic leukemia (ALL) are at increased risk of vitamin D deficiency, which might make
them more susceptible to developing adverse events. Previous studies showed that low vitamin D levels were associated with an
increased inflammatory mucosal state and impaired mucosal tissue barriers. We examined the prevalence of vitamin D deficiency
and studied the association between vitamin D levels and methotrexate (MTX)-induced oral mucositis in pediatric ALL.
Methods We assessed 25-hydroxyvitamin D (25(OH)D3) and 24,25-dihydroxyvitamin D (24,25(OH)2D3) levels in 99 children
with ALL before the start of 4 × 5 g/m2 high-dose methotrexate (HD-MTX) (T0) and in 81/99 children after discontinuation of
HD-MTX (T1). Two cutoff values for vitamin D deficiency exist: 25(OH)D3 levels < 30 and < 50 nmol/L. Oral mucositis was
defined as grade ≥ 3 according to the National Cancer Institute Criteria.
Results Vitamin D deficiency occurred in respectively 8% (< 30 nmol/L) and 33% (< 50 nmol/L) of the patients at T0, and more
frequently in children > 4 years of age as compared to children between 1 and 4 years of age. A decrease in 25(OH)D3 levels
during HD-MTX therapy was associated with developing severe oral mucositis (OR 1.6; 95% CI [1.1–2.4]). 25(OH)D3 and
24,25(OH)2D3 levels at T0 and the change in 24,25(OH)2D3 levels during therapy were not associated with the development of
severe oral mucositis.
Conclusions This study showed that vitamin D deficiency occurs frequently in pediatric ALL patients above the age of 4 years. A
decrease in 25(OH)D3 levels during MTX therapy was observed in children with ALL that developed severe oral mucositis.
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Introduction
Five-year survival rates of children with acute lymphoblastic
leukemia (ALL) have currently reached 90% in developed
countries [1, 2]. As treatment outcome has improved substan-
tially, more research focuses on strategies to reduce toxic side
effects from drugs such as methotrexate (MTX). Identifying
risk factors of high-dose methotrexate (HD-MTX)-induced
adverse events, such as oral mucositis, would be valuable to
develop preventive interventions. We previously showed that
oral mucositis occurs in 20% of pediatric ALL patients during
HD-MTX (5 g/m2) courses. [3]
A relat ion between vi tamin D defic iency and
chemotherapy-induced oral mucositis has been suggested in
a case report of a 59-year-old patient with breast carcinoma
receiving a treatment regimen of docetaxel, carboplatin, and
trastuzumab [4]. Vitamin D is a fat-soluble vitamin and im-
portant hormone involved in many physiological processes in
the human body, such as bone mineralization, insulin regula-
tion, and immune regulation [5–7]. Previous studies showed
that the vitamin D receptor is expressed in the mucosa and that
a relation exists between low vitamin D levels and an in-
creased inflammatory mucosal state and impaired mucosal
tissue barriers [8–10]. The main sources of vitamin D are
production in the skin through sunlight exposure, diet, and
vitamin D supplements [7, 11]. Vitamin D (D2 and D3) is
hydroxylated in the liver to 25-hydroxyvitamin D
(25(OH)D) and is converted into 1,25-dihydroxyvitamin D
(1,25(OH)2D) or into 24,25-dihydroxyvitamin D
(24,25(OH)2D3).
Children with ALL may be at increased risk of vitamin D
deficiency due to impaired sun exposure and impaired vitamin
intake [12]. A retrospective study in 86 pediatric cancer pa-
tients with a median age of 7 years revealed vitamin D defi-
ciency in 63% at diagnosis [13]. In childhood cancer survi-
vors, vitamin D deficiency was more prevalent than in control
subjects [14, 15]. Declining vitamin D levels during
anthracycline- and docetaxel-based chemotherapy regimens
were observed in 20 adult breast cancer patients [16]. In adult
cancer patients, no difference in chemotherapy-related toxici-
ty, including mucositis, was found between patients with and
without vitamin D deficiency [17]. However, this study cohort
consisted of patients with various malignancies and different
treatment regimens and numbers were too small. Until now,
no studies have examined the possible role of vitamin D in
relation to MTX-induced oral mucositis in pediatric cancer
patients.
This prospective study aimed to determine the prevalence
of vitamin D deficiency after ALL induction therapy before
the start of HD-MTX treatment, and to examine whether vita-
min D levels and a change in vitamin D levels during high-
doseMTX treatment were associated with the development of
MTX-induced mucositis in children with ALL.
Materials and methods
Patient selection and toxicity evaluation
Pediatric ALL patients (1–19 years) treated according to the
standard and medium risk arms of the Dutch Childhood
Oncology Group ALL-10 protocol between 2004 and 2012
were eligible for this study [2]. The study was approved by the
Medical Ethical Committee (MEC-2005-358) and written in-
formed consent was obtained from patients and their parents.
Detailed information on this protocol and cohort has been
previously described [3]. HD-MTX-induced oral mucositis
was used as clinical endpoint in this study and was scored
prospectively before, during, and after each high-dose MTX
course and at the end of protocol M according to the National
Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events v.3.0 score system by trained clinicians and
nurse specialists on a standardized clinical record forms [18].
Clinically relevant oral mucositis was defined as NCI grade ≥
3 (confluent ulcerations, bleeding with minor trauma; symp-
tomatic and unable to adequately aliment or hydrate orally).
According to the guideline of the Dutch Health Council, 10μg
vitamin D supplementation per day is recommended in chil-
dren until the age of 4 years [19].
Vitamin D levels: 25(OH)D2, 25(OH)D3,
and 24,25(OH)2D3
Peripheral blood samples for measurement of vitamin D levels
were collected before the start of protocolM (T0) and 2 weeks
after discontinuation of protocol M (T1) (Supplemental
Fig. 1). All serum samples were stored at − 80 °C and ana-
lyzed collectively. The 25(OH)D2, 25(OH)D3, and
24,25(OH)2D3 levels were analyzed using isotope dilution
liquid chromatography tandem mass spectrometry (ID-LC-
MS/MS), with detection limits for the three compounds of
0.36, 1.19, and 0.12 nmol/L, respectively. Intra-assay coeffi-
cients of variation (CVs) were 3, 3, and 5%, while inter-assay
CVs were 6, 6, and 9% for 25(OH)D2, 25(OH)D3, and
24,25(OH)2D3, respectively. The 25(OH)D3/24,25(OH)2D3
ratio was calculated as previously described [20]. Vitamin D
deficiency was defined as both 25(OH)D3 levels of < 30 and
of <50 nmol/L, as controversy exists on the correct cutoff
value [19, 21, 22].
Statistical analysis
The chi-square test was used to compare differences in the
prevalence of vitamin D deficiency between patients with
and patients without oral mucositis. The independent t test
(normally distributed variables) and Mann-Whitney U test
(skewed variables) were used to compare mean or median
25(OH)D2, 25(OH)D3, and 24,25(OH)2D3 levels and the
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25(OH)D3/24,25(OH)2D3 ratio at T0 and the change in these
levels between T0 and T1 (delta T1–T0) in patients with and
without oral mucositis. A p value < 0.05 was considered sig-
nificant. Logistic regression analysis was used to examine the
strength of the associations between 25(OH)D2, 25(OH)D3,
and 24,25(OH)2D3 levels and the 25(OH)D3/24,25(OH)2D3
ratio (T0 and delta T1–T0) and oral mucositis. We performed
univariable logistic regression analyses with the vitamin D
indicators as independent variables and oral mucositis as a
dependent variable. Subsequently, associations were adjusted
for possible confounders, such as age, sex, season, ALL risk
group, ALL immunophenotype, and body mass index (BMI),
in a multivariable logistic regression analysis. Possible con-
founders were included when they had a p value < 0.20 in
univariable analysis with both the determinant (vitamin D
levels) and the outcome (oral mucositis NCI grade ≥ 3) and
when they changed theβ in logistic regression analysis > 10%
[23, 24]. All analyses of the association between the change in
vitamin D levels and the development of oral mucositis were
corrected for vitamin D levels at T0.
Results
Patient characteristics
In total, 99 children with ALL were eligible for this study
(Fig. 1). We obtained samples for analysis in all patients at
baseline (T0) and in 81/99 patients after discontinuation of
HD-MTX (T1). Baseline characteristics of the patients are
summarized in Table 1. Twenty-three patients (23%) de-
veloped MTX-induced oral mucositis NCI grade ≥ 3 dur-
ing treatment.
Possible confounders
In univariable analysis, none of the possible confounders
met the criteria for inclusion in the multivariate models
(Supplemental Table 1a + 1b). In univariable analysis,
25(OH)D3 levels were significantly higher (mean ± SE,
76.1 ± 3.2 nmol/L) in the age category B1–4 years^ versus
the age category B> 4 years^ (mean ± SE, 52.8 ± 2.9 nmol/
L) (p < 0.001). Furthermore, 25(OH)D3 levels were signif-
icantly lower in patients with a high BMI ≥ 25 (mean ± SE,
21.3 ± 6.1) versus patients with a normal BMI 18–25
(mean ± SE, 58.8 ± 4.4) and patients with a low BMI <
18 (mean ± SE, 68.5 ± 3.1) (p < 0.001). However, age and
BMI were not associated with the development of severe
oral mucositis and did not change the β in logistic regres-
sion analysis > 10% and were therefore not considered
possible confounders in this study.
Vitamin D levels and vitamin D deficiency in children
with ALL before the start of HD-MTX treatment (T0)
Levels of 25(OH)D2 (median 0.7 nmol/L [0.4–1.3]),
25(OH)D3 (mean 63.1 ± 2.4 nmol/L) and 24,25(OH)2D3 (me-
dian 5.2 nmol/L [2.8–7.4]) and the 25(OH)D3/24,25(OH)2D3
ratio (mean 13.6 ± 0.5) at T0 are reported in Table 2. Vitamin
D deficiency was present in 8% of the children using a cutoff
value of 25(OH)D3 < 30 nmol/L (age category B1–4 years^:
2% versus B> 4 years^: 13%) and in 33% of children using a
cutoff value of 25(OH)D3 < 50 nmol/L (age category B1–
4 years^: 11% versus B> 4 years^: 51%).
Vitamin D levels at T0 in relation to development
of HD-MTX-induced oral mucositis
In 23/99 samples, 25(OH)D2 levels were below the detection
limit of 0.36 nmol/L. In the remaining 76 samples, median
levels of 25(OH)D2 at T0 were low (0.7 nmol/L [0.4–1.3])
and were therefore not analyzed in relation to MTX-induced
oral mucositis as these levels were not clinically relevant
(Table 2). We used vitamin D deficiency with a cutoff value
< 50 nmol/L in further analyses as vitamin D deficiency with a
cutoff value < 30 nmol/L could not be analyzed, because the
number of cases in the vitamin D deficient group was too
small. 25(OH)D3 levels, 24,25(OH)2D3 levels, and the
25(OH)D3/24,25(OH)2D3 ratio analyzed as a continuous var-
iable at T0 were not significantly associated with severe
MTX-induced oral mucositis (Table 3).
Change in vitamin D levels between T0 and T1
in relation to the development of HD-MTX-induced
oral mucositis
25(OH)D3 levels decreased significantly between T0 and T1
during high-dose MTX therapy in patients with oral mucositis
NCI grade ≥ 3 (− 9.6 ± 14.3 nmol/L) as compared to patients
without oral mucositis NCI grade ≥ 3 (+ 2.4 ± 17.2 nmol/L)
(Fig. 2 + Table 4, p value = 0.012). A decrease of
25(OH)D3 level of 10 nmol/L during HD-MTX therapy
increased the odds of developing severe MTX-induced oral
mucositis 1.6-fold (OR 1.63 [1.11–2.38], p value < 0.012,
Table 4). Changes in levels of 24,25(OH)2D3 and the
25(OH)D3/24,25(OH)2D3 ratio between T0 and T1 were
not significantly associated with the development of
MTX-induced oral mucositis (Table 4).
Discussion
In this study, vitamin D deficiency occurred in respectively
8% (< 30 nmol/L) and 33% (< 50 nmol/L) of the patients
before the start of HD-MTX therapy, and more frequently in
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children older than 4 years of age. Vitamin D levels before the
start of high-dose MTX treatment were not associated with
developing MTX-induced oral mucositis, but during MTX
therapy a decrease in 25(OH)D3 levels was observed in chil-
dren with ALL that developed severe oral mucositis.
Currently, no consensus exists on optimal vitamin D serum
levels in children. In children, both 25(OH)D levels <
30 nmol/L and levels < 50 nmol/L have been defined as vita-
min D deficiency [21, 22]. Therefore, we reported vitamin D
levels with both cutoff values of < 30 and < 50 nmol/L. Using
the cutoff value of < 50 nmol/L in our cohort, 11% of the
children aged 1–4 years was vitamin D deficient compared
to 51% of the children aged > 4 years, suggesting that parents
and/or caregivers supplemented the children in the younger
age category according to the recommendations of the
National Health Council [19]. Previous literature showed that
vitamin D deficiency (< 50 nmol/L) occurred in 30% of Dutch
children in the general population at the age of 6 years [25].
Our data showed that in the age category B5–7 years,^ 53%
(10/19) of pediatric ALL patients was deficient. This higher
rate of vitamin D deficiency compared to the general popula-
tion may be due to impaired sun exposition and less intake of
vitamin D.
Our study showed a decrease in 25(OH)D3 levels during
MTX therapy in children with ALL developing oral mucositis
compared to children without oral mucositis, whereas vitamin
Fig. 1 Flowchart of patient
inclusion. ALL, acute
lymphoblastic leukemia; HD-
MTX, high-dose methotrexate;
DCOG, Dutch Childhood
Oncology Group; SNP, single-
nucleotide polymorphism; n,
number of patients; * one patient
had neurological damage before
the start of HD-MTX treatment,
one patients was transferred to
another hospital, one patient had
an adjusted protocol due to a
SPINKS mutation, and one pa-
tient was initially treated other-
wise due to another diagnosis
Table 1 Patient characteristics (n = 99)
Median age at diagnosis, years (range) 5.7 (1.4–18.1)
Sex, n (%)
Female 55 (56%)
Male 44 (44%)
Risk group ALL treatment, n (%)
Standard risk 28 (28%)
Medium risk 71 (72%)
Immunophenotype ALL, n (%)
B-lineage 85 (86%)
T-lineage 14 (14%)
Median BMI, kg/m2 (range)a 17.3 (13.2–31.5)
Mucositis, n (%)
Mucositis ≥ NCI grade 3 23 (23%)
NCI National Cancer Institute
a BMI in eight patients missing
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D levels before the start of MTX therapy were not associated
with the development of oral mucositis. In this study, we were
not able to verify whether a decrease in vitamin D levels
preceded the occurrence of oral mucositis or vice versa. A
probable explanation could be that patients suffering from
severe oral mucositis are often admitted to the hospital where
they have a more impaired intake, have less sunlight exposure,
and might have impaired vitamin D uptake due to gastro-
intestinal mucositis compared to patients without oral muco-
sitis, causing a decrease in vitamin D levels. Subsequently, a
decrease in vitamin D levels may lead to an increased inflam-
matory state of the mucosa. The pathobiology of
chemotherapy-related oral mucositis is not well understood,
but is known to include an inflammatory part, in which both
cytokine release of TNFα, IL-6, and IL-1β and cellular infil-
tration of immune cells in the mucosa play a role [26]. Several
studies have implicated a relation between low vitamin D
levels and low vitamin D receptor expression and the devel-
opment of an increased inflammatory response in the mucosa,
such as in inflammatory bowel disease, by modulating T cell
receptor responses and cytokine release [8, 27]. Furthermore,
vitamin D deficiency has been implicated to play a role in
tissue barrier defects in the gastro-intestinal system [9, 28].
Therefore, it could very well be that decreasing vitamin D
Table 2 Vitamin D levels in pediatric ALL patients at the start of high-dose MTX treatment (T0)
Levels (nmol/L) Levels per age category (nmol/L)
25(OH)D2 Median (IQR) 0.7 (0.4–1.3) 1–4 years 0.5 (0.4–1.2)
> 4 years 1.0 (0.5–1.4)
25(OH)D3 Mean ± SE 63.1 ± 2.4 1–4 years 76.1 ± 3.2
> 4 years 52.8 ± 2.9
24,25(OH)2D3 Median (IQR) 5.2 (2.8–7.4) 1–4 years 6.4 (4.6–8.5)
> 4 years 4.2 (2.2–6.4)
Ratio Ratio per age category
25(OH)D3/24,25(OH)2D3 ratio Mean ± SE 13.6 ± 0.5 1–4 years 12.8 ± 0.7
> 4 years 14.2 ± 0.7
Vitamin D deficiency, n (%)a Vitamin D deficiency per age category, n (%)b
25(OH)D3 < 30 nmol/L 8 (8%) 1–4 years 1 (2%)
> 4 years 7 (13%)
< 50 nmol/L 33 (33%) 1–4 years 5 (11%)
> 4 years 28 (51%)
IQR interquartile range, SE standard error of the mean
a Percentage of total study group (n = 99)
b Percentages within age group B1–4 years^ (n = 44) and age group B> 4 years^ (n = 55)
Table 3 Vitamin D levels at T0 in
relation to HD-MTX-induced oral
mucositis (NCI grade ≥ 3)
Mucositis—no
n = 76
Mucositis—Yes
n = 23
p value OR 95% CI
25(OH)D3, nmol/L
Mean ± SE 62.3 ± 3.0 66.0 ± 3.7 0.528 1.006 (0.987–1.026)
25(OH)D3
< 30 nmol/L 8 (100%) 0 (0%) a a a
≥ 30 nmol/L 68 (75%) 23 (25%)
< 50 nmol/L 28 (85%) 5 (15%) 0.178 2.100 (0.703–6.277)
≥ 50 nmol/L 48 (73%) 18 (27%)
24,25(OH)2D3, nmol/L
Median (IQR) 5.3 (2.7–7.3) 4.8 (4.0–8.3) 0.494 1.047 (0.906–1.210)
25(OH)D3/24,25(OH)2D3 ratio
Mean ± SE 13.8 ± 0.6 12.8 ± 0.9 0.401 0.957 (0.864–1.060)
IQR interquartile range, SE standard error of the mean
a Power too low to perform statistical analysis
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levels aggravate the course of oral mucositis. This needs fur-
ther investigation as we did not have data on the length of the
mucositis period or on inflammatory cytokine levels.
We showed that 25(OH)D2 levels were often below (n =
23) and near (n = 76) the detection limit in children with ALL.
This is most likely due to the fact that over-the-counter sup-
plements in the Netherlands contain 25(OH)D3 and the rela-
tively small source of plant-derived 25(OH)D2 will not lead to
substantial plasma concentrations. As levels were very low, it
was not statistically possible and clinically relevant to analyze
these levels in relation to the development of MTX-induced
oral mucositis.
Although 1,25(OH)2D is known as the active vitamin D
metabolite, it is a poor indicator of overall vitamin D status
as serum 1,25(OH)2D is often increased in patients with
vitamin D deficiency due to secondary hyperparathyroid-
ism [29]. Until recently, 24,25(OH)2D3 was considered an
inactive metabolite or degradation product of 25(OH)D.
However, several reports suggested that 24,25(OH)2D3
possesses biological activity and that 24,25(OH)2D3 levels
and the 25(OH)D/24,25(OH)2D ratio reflect the vitamin D
status [20, 30–33].
High BMI (≥ 25) was present in four patients and these
patients had very low 25(OH)D3 levels compared to patients
with a normal BMI and an underweight BMI. This is in line
with previous literature that showed that vitamin D deficiency
occurs more frequently in obese cancer patients [34].
Proposed underlyingmechanisms of this phenomenon include
lack of sunlight due to less physical activity in obese patients
and less bio-availability due to deposition of vitamin D in
subcutaneous fat depots [35, 36].
Another important factor to take into account in future
studies is the bio-availability of vitamin D. Vitamin D is large-
ly bound to vitamin D-binding proteins (VDBP) and albumin.
Lower levels of VDBP and albumin increase bio-availability
Fig. 2 25(OH)D3 levels at T0 and T0 in relation to the development of
oral mucositis. 25(OH)D3 levels at T0 and T1 in individual patients with
(yes, n = 62) and without (no, n = 19) mucositis; the red lines indicate the
mean 25(OH)D3 levels at T0 and T1 of all patients; the blue lines indicate
the 95% confidence interval; the dotted line indicates the cutoff value of
vitamin D deficiency at 25(OH)D3 levels < 50 nmol/L.
Table 4 Change vitamin D levels in relation to HD-MTX-induced oral mucositis (NCI grade ≥ 3)
Mucositis—no
n = 62
Mucositis—yes
n = 19
p value p value correcteda OR (95% CI) 1/OR (95% CI)b
Delta 25(OH)D3, nmol/L
Mean ± SE 2.4 ± 2.2 − 9.6 ± 3.3 0.007* 0.012* Per 1 nmol/L, 0.953 (0.917–0.989) 1.05 (1.01–1.09)
Per 10 nmol/L, 0.615 (0.421–0.899) 1.63 (1.11–2.38)
Delta 24,25(OH)2D3, nmol/L
Median (IQR) − 0.1 (− 1.7–0.9) − 1.2 (− 1.9–0.4) 0.160 0.447 Per 1 nmol/L, 0.912 (0.721–1.155) 1.10 (0.87–1.39)
Delta 25(OH)D3/24,25(OH)2D3 ratio
Mean ± SE 0.3 ± 0.5 0.6 ± 0.8 0.818 0.930 0.993 (0.840–1.173) 1.01 (0.85–1.19)
IQR interquartile range, SE standard error of the mean
*p value < 0.05
a Corrected for 25(OH)D3, 24,25(OH)2D3, and 25(OH)D3/24,25(OH)2D3 ratio at T0 respectively in multivariable logistic regression model
bWe performed 1/OR (95% CI) as we reported the analysis as an increased risk and not as a decreased risk of developing oral mucositis
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and therefore the same level of vitamin D could have a differ-
ent biological meaning in patients with different levels of
VDBP and albumin [30].
Strengths of this study are the prospective collection of
samples and toxicity data and the accuracy of the vitamin
metabolite measurements. Limitations are the fact that possi-
ble confounders, such as vitamin D supplementation, nutri-
tional status, VDBP levels, and inflammatory markers, were
not studied. These factors could be taken into account in future
studies to get insight into a possible mechanism.
In conclusion, the prevalence of vitamin D deficiency was
high in children with ALL above the age of 4 years. Although
we did not find an association between low baseline vitamin D
levels with MTX-induced oral mucositis in children with
ALL, 25(OH)D3 levels decreased significantly during MTX
therapy in patients with severe MTX-induced oral mucositis.
This should be further examined as vitamin D supplementa-
tion is a very easy intervention.
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